Provided by Tiger Fintech (Singapore) Pte. Ltd.

enVVeno Medical Corp.

4.07
-0.1000-2.40%
Post-market: 4.00-0.0700-1.72%19:58 EDT
Volume:108.28K
Turnover:443.54K
Market Cap:71.37M
PE:-3.48
High:4.21
Open:4.19
Low:4.00
Close:4.17
Loading ...

enVVeno Medical announces interim two-year follow-up data on VenoValve trial

TIPRANKS
·
06 Jun

enVVeno Medical Corp. Files Initial Statement of Beneficial Ownership for CFO Jennifer Bright

Reuters
·
21 May

enVVeno Medical Names Jennifer Bright CFO

MT Newswires Live
·
19 May

enVVeno Medical appoints Jennifer Bright as CFO

TIPRANKS
·
19 May

enVVeno Medical Corp. Appoints Jennifer Bright as New Chief Financial Officer

Reuters
·
19 May

enVVeno Medical reports Q1 EPS (22c) vs. (31c) last year

TIPRANKS
·
01 May

enVVeno Medical Says Ended Q1 2025 With $38.9M In Cash, Investments

Benzinga
·
01 May

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

ACCESS Newswire
·
01 May

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

ACCESS Newswire
·
23 Apr

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

ACCESS Newswire
·
16 Apr

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

ACCESS Newswire
·
31 Mar

BRIEF-enVVeno Medical Files For Mixed Shelf Of Up To $100 Million - SEC Filing

Reuters
·
01 Mar

enVVeno Medical files $100M mixed securities shelf

TIPRANKS
·
01 Mar

enVVeno Medical Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

enVVeno Medical FY 2024 GAAP EPS $(1.27) Beats $(1.32) Estimate

Benzinga
·
28 Feb

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

ACCESS Newswire
·
28 Feb

enVVeno Medical Corp expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
25 Feb

enVVeno Medical presents one-year data from VenoValve trial

TIPRANKS
·
19 Feb

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

ACCESS Newswire
·
19 Feb

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

ACCESS Newswire
·
07 Feb